SD-1029 is a Janus kinase 2 (JAK2) inhibitor. It inhibits autophosphorylation of recombinant JAK2 when used at concentrations of 30 and 100 μM and decreases levels of phosphorylated JAK2, but not JAK1 or Src, in MDA-MB-468 and paclitaxel-resistant OVCAR8TR cells when used at a concentration of 10 μM. SD-1029 (10 μM) decreases levels of phosphorylated STAT3 in MDA-MB-468, MDA-BM-435, OVCAR8TR, and SKOV3TR cells and inhibits IL-6-induced nuclear translocation of STAT3 in BHK-21 and U2OS cells. It decreases the viability of and increases levels of cleaved caspase-3 in SNU-387, SNU-398, HepG2, and Huh7 hepatocellular carcinoma cells when used at a concentration of 10 μM. SD-1029 (100 and 1,000 nM) inhibits hepatitis A virus replication in GL37 cells.
